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Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia 
worldwide. Patients display a highly variable clinical course, with some requiring 
immediate therapeutic intervention while others can remain untreated for years. We 
have previously reported that DNA methylation of the homeobox A4 (HOXA4) promoter 
can serve as part of a three gene prognostic signature with CD38 and BTG4 to predict 
time to first treatment (TTT) in Stage A patients. HOXA4 encodes a transcription factor 
that is expressed in haematopoietic progenitor cells and is involved in embryonic 
development and B-cell differentiation, and its aberrant epigenetic regulation has been 
identified in multiple forms of leukaemia. In this study we have sought to elucidate the 
role of HOXA4 in the progression of CLL and determine the functional consequences of 
its expression. 
 
We analysed DNA methylation of the HOXA4 promoter by pyrosequencing in a 
heterogeneous cohort of 163 CLL patients (median age: 70; median follow-up: 10 
years), of whom 60% were Binet Stage A, 16% Stage B and 24% Stage C. Data was 
collected regarding treatment history, TTT and overall survival, as well as cytogenetic 
abnormalities and IGVH mutation status. HOXA4 methylation increased with disease 
progression and was significantly higher in Stage C patients (median 74%) than those 
with Stage A (62%; p = 0.03) and Stage B disease (65%; p < 0.05). HOXA4 methylation 
was positively correlated with IGVH sequence homology (r = 0.34, p < 0.0001) and 
negatively associated with TTT among patients who have started chemotherapy (p = 
0.04) and with overall survival (p = 0.04). No associations were observed between 
HOXA4 methylation and 11q, 13q or 17p deletions, or TP53 and ATM mutations. 
 
To investigate the role of HOXA4 in the evolution of the disease, we analysed samples 
taken at multiple timepoints from 42 patients, of whom 29 were undergoing treatment 
and 13 remained untreated. HOXA4 methylation significantly increased in patients 
undergoing treatment (p = 0.01), but did not differ in untreated patients (p = 0.19). 
 
We hypothesised that silencing of HOXA4 may be selected for during treatment due to 
its expression conferring increased sensitivity to chemotherapy. Using a lentiviral 
system, we observed that re-expression of HOXA4 increased drug sensitivity in a 
malignant differentiated B-cell line (Raji). Significantly higher apoptosis was identified 
after treatment with 3 M and 10 M fludarabine (both p < 0.001) and 1 M and 10 M 
ibrutinib (p < 0.01 and p < 0.001), but not 1 M and 10 M idelalisib. 
 
To confirm the translational relevance our observations, we overexpressed HOXA4 in 
primary CLL cells derived from four patients and confirmed increased apoptosis in 
response to 3 M and 10 M fludarabine treatment in comparison to control cells (p = 
0.02 and p < 0.01). Further work is underway in primary CLL cells to elucidate the 
pathways under the control of HOXA4 that may confer this drug sensitivity. 
 
Our ongoing work may indicate that HOXA4 is also implicated in the progression of CLL 
through directing malignant cells to the protective bone marrow niche, thereby further 
reducing sensitivity to antimetabolites. In cell lines HOXA4 up-regulates the expression 
of RGS2 and RGS16, which are negative regulators of the CXCR4-CXCL12 signalling 
axis, and we have identified selection for biallelic HOXA4 methylation in primary acute 
lymphoblastic leukaemia cells following engraftment in mice (median in primary cells: 
80%; engrafted cells: 92%; p < 0.0001). 
 
To determine the origins of HOXA4 dysregulation during the course of the disease, we 
analysed prospective blood samples from the European Prospective Investigation into 
Cancer and Nutrition (EPIC) from 20 individuals diagnosed with CLL up to 17 years after 
blood draw (median: 7 years) and 20 age-matched controls who remained free of 
cancer. We observed that HOXA4 methylation was significantly higher among future 
CLL patients (median: 49% vs 42%; p = 0.01) and was inversely correlated with time to 
diagnosis, but did not reach statistical significance (r = -0.39, p = 0.09). 
 
Together, our findings suggest that silencing of the HOXA4 gene is an early event in 
CLL which is selected for during the course of disease through reduced sensitivity to 
chemotherapeutic agents. Our ongoing work will identify downstream targets that may 
be implicated in conferring sensitivity, and which may serve as biomarkers to predict 
prognosis and inform treatment strategies. 
